Anacetrapib, a CETP inhibitor, decreased the incidence of major coronary events among patients with atherosclerotic vascular disease when given on top of intensive statin therapy.

Circadian disruption with concurrent sleep restriction (< 6 hours/day) can lead to decrease in bone formation in young adults.

Liraglutide,an injectable diabetic drug, when given in type 2 diabetes at high cardiovascular risk, resulted in lower rates of development and progression of diabetic kidney disease.

Over 80% of patients with diabetes secondary to a pancreatic disease (Type 3c) were misdiagnosed as type 2 diabetes according to a recent study  done in England.These patients have worse glycemic control and tend to require insulin more often than not as compared to type 2 diabetics.

Patients with severe obesity who underwent gastric bypass were found to have sustained weight loss at 12 years with an average weight loss of 35%. Half of those who had diabetes were non-diabetic at 12 years.

Sotagliflozin, an oral anti diabetic drug, when added to insulin was found to help improve glycemic control, blood pressure and body weight in people with type 1 diabetes. However it was found to raise the risk of ketoacidosis